LUCIA pivotal Phase 3 trial continues rapid enrollment pace with 60% of patients randomized; enrollment completion expected in 3Q 2025 – – Topline 56-week data for LUGANO expected in mid-2026 with ...

Thanks to advancements in early detection and treatment options, it's possible to live a long and healthy life after being ...

CAMBRIDGE - Joan W. Miller, MD—the David Glendenning Cogan Professor of Ophthalmology and Chair of Ophthalmology at Harvard Medical School and Chair of Ophthalmology at Massachusetts Eye and Ear and ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

2 Bakall B, Folk JC, Boldt HC, et al. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol. 2013;156(1):15–22. 3 Ho VY ...

Shares of Ocular Therapeutix (NASDAQ:OCUL) spiked on Wednesday after the company said its Phase 3 registrational trial SOL-R ...

There has been a lot of talk about drugs targeting both PD-1 and VEGF stealing the crown held by MSD's Keytruda in cancer immunotherapy. Now, the company has made a move to try to make sure it isn ...